My update, as promised: Last week I asked for... - CLL Support

CLL Support

22,370 members38,479 posts

My update, as promised

Ducksoup profile image
3 Replies

Last week I asked for information on obinotuzumab treatment for my CLL--were my responses normal? I received tremendously valuable information and support from the community. I promised an update.

Wonderful news! When I came in on October 24 for my first treatment my lymphocyte count was 154K. When I came for the second treatment on October 31 that number had dropped to 10K. WBC was down to just over 14K--a drop of 150,000 in a single week. No wonder I was tired. I was busy busy busy!

I have a great deal more energy, stamina, and far less fatigue this week than last. I no longer have sweats. I'm no longer dizzy/woozy.

Can't wait to see my numbers on Monday. Tuesday is election day and we hope the foul air around us will clear. Well, we can hope, can't we? It could be a very good week.

Thank you all!

Written by
Ducksoup profile image
Ducksoup
To view profiles and participate in discussions please or .
3 Replies
Peggy4 profile image
Peggy4

Wow ducksoup! Lovely to hear. You must be feeling pretty good right now.😀

Peggy

prosecco1 profile image
prosecco1

Brilliant news, good luck for Monday

Elle x 👍

Bethan49 profile image
Bethan49

Well done you! Our lives become ruled by numbers... goid luck for Monday x

You may also like...

Ibrutinib my story update

denied Ibrutinib for my relapsed CLL. On Friday last week I contacted the Nottingham Evening Post...

Update on my skin rash

(6th) that I had on November 4th . I had started to wonder myself as I have had nothing like this...

My Dana-Farber Trial Update

the first week. Called my care team. Tylenol basically stopped the headaches. They never came back....

Update from my Appointment

and had excellent information. 2.My blood work is totally out of whack. Of note, my WBC is 130,...

Update re visit to Moffit in Tampa to see my Hematologist

3 choices: Number One: Bendamustine with Rituxan........Number Two: Ibrutinib...Number Three:...